Logo
x

Search

Subscribe Now

astellas

Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients

Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients

  • August 27, 2024
Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology

Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology

  • May 2, 2024
EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment

EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment

  • April 24, 2024
Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer

Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer

  • March 29, 2024
Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan

Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan

  • March 4, 2024
Astellas Reports the Submission of sNDA to the Japan MHLW for Padcev in Combination with Keytruda to Treat Advanced Bladder Cancer

Astellas Reports the Submission of sNDA to the Japan MHLW for Padcev in Combination with Keytruda to Treat Advanced Bladder Cancer

  • January 31, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.